The Sosei Group has been granted a patent for compounds that act as agonists of the muscarinic M1 and/or M4 receptors. These compounds have potential therapeutic uses in treating diseases mediated by these receptors. The patent also covers pharmaceutical compositions containing these compounds. GlobalData’s report on Sosei Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Sosei Group Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11773090B2) discloses a compound of the formula (1) and its pharmaceutically acceptable salts. The compound has various substituents, including R2 being hydrogen and R4 being hydrogen or methyl. Additionally, the patent claims specific compounds falling within the defined formula, such as Ethyl 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate and Methyl 7-[4-(azepan-1-ylcarbonyl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, among others.

Furthermore, the patent claims a pharmaceutical composition comprising the compound of formula (1) or its pharmaceutically acceptable salt, along with a pharmaceutically acceptable excipient. This composition can be used for the treatment of cognitive disorders, psychotic disorders, and the management of acute, chronic, neuropathic, or inflammatory pain. The method involves administering an effective amount of the compound or its salt to individuals suffering from these conditions.

Specifically, the patent highlights the potential use of the compound in treating cognitive disorders such as Alzheimer's disease, dementia with Lewy bodies, and schizophrenia. These disorders are characterized by cognitive impairment and can greatly impact the quality of life for affected individuals. By administering the compound, the severity of symptoms associated with these disorders can be reduced or treated effectively.

Overall, this granted patent presents a compound and its pharmaceutically acceptable salts, along with their potential use in pharmaceutical compositions for the treatment of cognitive disorders, psychotic disorders, and pain management. The specific compounds claimed in the patent offer potential therapeutic options for conditions like Alzheimer's disease, dementia with Lewy bodies, and schizophrenia. This patent provides valuable insights for researchers and pharmaceutical companies working in the field of cognitive and psychotic disorders, as well as pain management.

To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies